cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.19114575.v1
title: simulation_data.csv from Temporary prey storage along swarm columns of army ants: an adaptive strategy for successful raiding?

description: While pillaging the brood of other ant colonies, <i>Eciton</i> army ants accumulate prey in piles, or caches, along their foraging trails. Widely documented, these structures have historically been considered as by-products of heavy traffic or aborted relocations of the ants' temporary nest, or bivouac. However, we recently observed that caches of the hook-jawed army ant, <i>Eciton hamatum</i>, appeared independently from heavy traffic or bivouac relocations. In addition, the flow of prey through caches varied based on the quantity of prey items workers transported. As this suggested a potential adaptive function, we developed agent-based simulations to compare raids of caching and non-caching virtual army ants. We found that caches increased the amount of prey that relatively low numbers of raiders were able to retrieve. However, this advantage became less conspicuous—and generally disappeared—as the number of raiders increased. Based on these results, we hypothesize that caches maximize the amount of prey that limited amounts of raiders can retrieve, especially as prey colonies coordinately evacuate their brood. In principle, caches also allow workers to safely collect multiple-prey items and efficiently transport them to the bivouac. Further field observations are needed to test this and other hypotheses emerging from our study.
DOI: 10.6084/m9.figshare.19114575
title: simulation_data.csv from Temporary prey storage along swarm columns of army ants: an adaptive strategy for successful raiding?

description: While pillaging the brood of other ant colonies, <i>Eciton</i> army ants accumulate prey in piles, or caches, along their foraging trails. Widely documented, these structures have historically been considered as by-products of heavy traffic or aborted relocations of the ants' temporary nest, or bivouac. However, we recently observed that caches of the hook-jawed army ant, <i>Eciton hamatum</i>, appeared independently from heavy traffic or bivouac relocations. In addition, the flow of prey through caches varied based on the quantity of prey items workers transported. As this suggested a potential adaptive function, we developed agent-based simulations to compare raids of caching and non-caching virtual army ants. We found that caches increased the amount of prey that relatively low numbers of raiders were able to retrieve. However, this advantage became less conspicuous—and generally disappeared—as the number of raiders increased. Based on these results, we hypothesize that caches maximize the amount of prey that limited amounts of raiders can retrieve, especially as prey colonies coordinately evacuate their brood. In principle, caches also allow workers to safely collect multiple-prey items and efficiently transport them to the bivouac. Further field observations are needed to test this and other hypotheses emerging from our study.
DOI: 10.48370/ofd/0nosjv/rklba6
title: Mycosphaerella filicum (Desmazières) Starbäck F-2487.tif

description: :unav
DOI: 10.48370/ofd/0nosjv
title: Mycosphaerella filicum (Desmazières) Starbäck, 2487

description: Fungarium Micromycetes
DOI: 10.48370/ofd/v2ai7m/sozjg2
title: Mycosphaerella harthensis (Auersw.) Mig. F-0611 (2).tif

description: :unav
DOI: 10.48370/ofd/v2ai7m/gleboq
title: Mycosphaerella harthensis (Auersw.) Mig. F-0611 (3).tif

description: :unav
DOI: 10.48370/ofd/v2ai7m/crcirc
title: Mycosphaerella harthensis (Auersw.) Mig. F-0611.tif

description: :unav
DOI: 10.48370/ofd/v2ai7m/7k0i3w
title: Mycosphaerella harthensis (Auersw.) Mig. F-0611 (4).tif

description: :unav
DOI: 10.48370/ofd/llavax/pf7azd
title: Mycosphaerella hypostomatica Hőhnel F-4483.tif

description: :unav
DOI: 10.48370/ofd/llavax
title: Mycosphaerella hypostomatica Hőhnel, 4483

description: Fungarium Micromycetes
DOI: 10.48370/ofd/v2ai7m
title: Mycosphaerella harthensis (Auersw.) Mig., 611

description: Fungarium Micromycetes
DOI: 10.48370/ofd/kqbarg/yyone7
title: Mycosphaerella longissima (Fuck.) Lindau F-4403.tif

description: :unav
DOI: 10.48370/ofd/kqbarg
title: Mycosphaerella longissima (Fuck.) Lindau, 4403

description: Fungarium Micromycetes
DOI: 10.48370/ofd/ylp75v/kbth2h
title: Mycosphaerella punctiformis (Persoon) Starback F-2754.tif

description: :unav
DOI: 10.48370/ofd/ylp75v
title: Mycosphaerella punctiformis (Persoon) Starback, 2754

description: Fungarium Micromycetes
DOI: 10.48370/ofd/kpbugl/u4dsfh
title: Mycosphaerella punctiformis (Persoon) Starback F-1818 (4).tif

description: :unav
DOI: 10.48370/ofd/kpbugl/dwgrxz
title: Mycosphaerella punctiformis (Persoon) Starback F-1818.tif

description: :unav
DOI: 10.48370/ofd/kpbugl/61eq3z
title: Mycosphaerella punctiformis (Persoon) Starback F-1818 (3).tif

description: :unav
DOI: 10.48370/ofd/kpbugl/ab5hrx
title: Mycosphaerella punctiformis (Persoon) Starback F-1818 (2).tif

description: :unav
DOI: 10.48370/ofd/kpbugl
title: Mycosphaerella punctiformis (Persoon) Starback, 1818

description: Fungarium Micromycetes
DOI: 10.48370/ofd/ggauas/mzkfut
title: Mycosphaerella punctiformis (Persoon) Starback F-1368 (2).tif

description: :unav
DOI: 10.48370/ofd/ggauas/zxvn3f
title: Mycosphaerella punctiformis (Persoon) Starback F-1368 (3).tif

description: :unav
DOI: 10.48370/ofd/ggauas/u7ih9x
title: Mycosphaerella punctiformis (Persoon) Starback F-1368.tif

description: :unav
DOI: 10.48370/ofd/ggauas/4kdy12
title: Mycosphaerella punctiformis (Persoon) Starback F-1368 (5).tif

description: :unav
DOI: 10.48370/ofd/bhbbp9/amyz6z
title: Mycosphaerella punctiformis (Persoon) Starback F-2329 (3).tif

description: :unav
DOI: 10.48370/ofd/bhbbp9/q04xhu
title: Mycosphaerella punctiformis (Persoon) Starback F-2329 (2).tif

description: :unav
DOI: 10.48370/ofd/ggauas/mzgm6g
title: Mycosphaerella punctiformis (Persoon) Starback F-1368 (4).tif

description: :unav
DOI: 10.48370/ofd/ggauas
title: Mycosphaerella punctiformis (Persoon) Starback, 1368

description: Fungarium Micromycetes
DOI: 10.48370/ofd/bhbbp9/fnk3sz
title: Mycosphaerella punctiformis (Persoon) Starback F-2329.tif

description: :unav
DOI: 10.48370/ofd/bhbbp9/wcuetq
title: Mycosphaerella punctiformis (Persoon) Starback F-2329 (4).tif

description: :unav
DOI: 10.48370/ofd/bhbbp9/uoa4p3
title: Mycosphaerella punctiformis (Persoon) Starback F-2329 (5).tif

description: :unav
DOI: 10.48370/ofd/bhbbp9
title: Mycosphaerella punctiformis (Persoon) Starback, 2329

description: Fungarium Micromycetes
DOI: 10.48370/ofd/mensva/gy0srg
title: Mycosphaerella punctiformis (Persoon) Starback F-1380.tif

description: :unav
DOI: 10.48370/ofd/mensva
title: Mycosphaerella punctiformis (Persoon) Starback, 1380

description: Fungarium Micromycetes
DOI: 10.5281/zenodo.5913335
title: Quantitative raw data for D1.3 - "Requirements and motivations of quadruple helix stakeholders for active engagement in the Citizen Science"

description: This dataset presents the quantitative raw data that was collected under the H2020 INCENTIVE project for the D1.3 - “Requirements and motivations of quadruple helix stakeholders for active engagement in the Citizen Science Hubs”. The dataset includes the answers that were provided by almost 2,000 participants from 4 pilot European countries (Greece, Lithuania, Spain, and the Netherlands) regarding the general public's perceptions, attitudes, concerns, motivational factors and obstacles with regard to participation in Citizen Science activities. The original survey questionnaire was created and disseminated through the EUSurvey platform, and data collection took place from April to June 2021. For the statistical analysis of the data and the conclusions drawn from the analysis, you can access the D1.3 - "Requirements and motivations of quadruple helix stakeholders for active engagement in the Citizen Science Hubs”. Under INCENTIVE, four Citizen Science Hubs will be established and tested during the life-span of the project in the facilities of four Research Performing and Funding Organisations (RPFOs): University of Twente (the Netherlands), Autonomous University of Barcelona (Spain), Aristotle University of Thessaloniki (Greece) and Vilnius Gediminas Technical University (Lithuania). Essentially, the Hubs will aim to bring different stakeholders together and bridge society with science under the emerging paradigm of Citizen Science, in an institutionalised way.
description: The INCENTIVE project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement no. 101005330
DOI: 10.5281/zenodo.5913334
title: Quantitative raw data for D1.3 - "Requirements and motivations of quadruple helix stakeholders for active engagement in the Citizen Science"

description: This dataset presents the quantitative raw data that was collected under the H2020 INCENTIVE project for the D1.3 - “Requirements and motivations of quadruple helix stakeholders for active engagement in the Citizen Science Hubs”. The dataset includes the answers that were provided by almost 2,000 participants from 4 pilot European countries (Greece, Lithuania, Spain, and the Netherlands) regarding the general public's perceptions, attitudes, concerns, motivational factors and obstacles with regard to participation in Citizen Science activities. The original survey questionnaire was created and disseminated through the EUSurvey platform, and data collection took place from April to June 2021. For the statistical analysis of the data and the conclusions drawn from the analysis, you can access the D1.3 - "Requirements and motivations of quadruple helix stakeholders for active engagement in the Citizen Science Hubs”. Under INCENTIVE, four Citizen Science Hubs will be established and tested during the life-span of the project in the facilities of four Research Performing and Funding Organisations (RPFOs): University of Twente (the Netherlands), Autonomous University of Barcelona (Spain), Aristotle University of Thessaloniki (Greece) and Vilnius Gediminas Technical University (Lithuania). Essentially, the Hubs will aim to bring different stakeholders together and bridge society with science under the emerging paradigm of Citizen Science, in an institutionalised way.
description: The INCENTIVE project has received funding from the European Union's Horizon 2020 research and innovation programme under Grant Agreement no. 101005330
DOI: 10.48370/ofd/zlfo3o/yqm6tt
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4340 (2).tif

description: :unav
DOI: 10.48370/ofd/zlfo3o/kx67dq
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4340 (3).tif

description: :unav
DOI: 10.48370/ofd/zlfo3o/hxhrmh
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4340.tif

description: :unav
DOI: 10.48370/ofd/zlfo3o
title: Neoërysiphe galeopsidis (DC.) U. Braun, 4340

description: Fungarium Micromycetes
DOI: 10.48370/ofd/tzfffk/ffmiap
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2544.tif

description: :unav
DOI: 10.48370/ofd/tzfffk
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2544

description: Fungarium Micromycetes
DOI: 10.48370/ofd/r4lksm/jelbhy
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2527.tif

description: :unav
DOI: 10.48370/ofd/r4lksm
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2527

description: Fungarium Micromycetes
DOI: 10.48370/ofd/elt8gb/y8usxa
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2462.tif

description: :unav
DOI: 10.48370/ofd/elt8gb
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2462

description: Fungarium Micromycetes
DOI: 10.25625/jepy8l/sijru2
title: 2022-2-JEPY8L_Tappe_data.tab

description: :unav
DOI: 10.48370/ofd/pymygj/ubafrj
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-0456.tif

description: :unav
DOI: 10.48370/ofd/pymygj
title: Neoërysiphe galeopsidis (DC.) U. Braun, 456

description: Fungarium Micromycetes
DOI: 10.48370/ofd/ojgo64/lufazl
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4389.tif

description: :unav
DOI: 10.48370/ofd/ojgo64
title: Neoërysiphe galeopsidis (DC.) U. Braun, 4389

description: Fungarium Micromycetes
DOI: 10.48370/ofd/zptcq1/oa0o5w
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2516.tif

description: :unav
DOI: 10.48370/ofd/zptcq1
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2516

description: Fungarium Micromycetes
DOI: 10.25625/flv19s/e8waw5
title: 2022-2-FLV19S_Tappe_data.xls

description: :unav
DOI: 10.48370/ofd/meslr5/u2ll0m
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2113.tif

description: :unav
DOI: 10.48370/ofd/meslr5
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2113

description: Fungarium Micromycetes
DOI: 10.48370/ofd/o4pdom/who1jq
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1996.tif

description: :unav
DOI: 10.48370/ofd/o4pdom
title: Neoërysiphe galeopsidis (DC.) U. Braun, 1996

description: Fungarium Micromycetes
DOI: 10.48370/ofd/sabssc/gcm6et
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1110 (4).tif

description: :unav
DOI: 10.48370/ofd/sabssc/5vzonv
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1110.tif

description: :unav
DOI: 10.48370/ofd/sabssc/bgmvgl
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1110 (5).tif

description: :unav
DOI: 10.48370/ofd/sabssc/ca5zoj
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1110 (3).tif

description: :unav
DOI: 10.48370/ofd/sabssc/bmolvh
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1110 (2).tif

description: :unav
DOI: 10.48370/ofd/sabssc
title: Neoërysiphe galeopsidis (DC.) U. Braun, 1110

description: Fungarium Micromycetes
DOI: 10.48370/ofd/bvkh3j/acivnu
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1221.tif

description: :unav
DOI: 10.48370/ofd/bvkh3j
title: Neoërysiphe galeopsidis (DC.) U. Braun, 1221

description: Fungarium Micromycetes
DOI: 10.48370/ofd/m4ygg3/nfzviu
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4556 (2).tif

description: :unav
DOI: 10.48370/ofd/m4ygg3/qgsziv
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4556.tif

description: :unav
DOI: 10.48370/ofd/m4ygg3/7mdgx8
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4556 (3).tif

description: :unav
DOI: 10.48370/ofd/m4ygg3/okqskg
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-4556 (4).tif

description: :unav
DOI: 10.48370/ofd/m4ygg3
title: Neoërysiphe galeopsidis (DC.) U. Braun, 4556

description: Fungarium Micromycetes
DOI: 10.48370/ofd/apizmu/mtdzom
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2503.tif

description: :unav
DOI: 10.48370/ofd/apizmu
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2503

description: Fungarium Micromycetes
DOI: 10.48370/ofd/zibtzj/ypc2eu
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-0719.tif

description: :unav
DOI: 10.48370/ofd/zibtzj
title: Neoërysiphe galeopsidis (DC.) U. Braun, 719

description: Fungarium Micromycetes
DOI: 10.48370/ofd/o6tulm/t6gbeg
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-1029.tif

description: :unav
DOI: 10.48370/ofd/o6tulm
title: Neoërysiphe galeopsidis (DC.) U. Braun, 1029

description: Fungarium Micromycetes
DOI: 10.48370/ofd/gkspum/iuhkif
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2581.tif

description: :unav
DOI: 10.48370/ofd/gkspum
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2581

description: Fungarium Micromycetes
DOI: 10.48370/ofd/nwwqhc/xqlmzf
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-2260.tif

description: :unav
DOI: 10.48370/ofd/nwwqhc
title: Neoërysiphe galeopsidis (DC.) U. Braun, 2260

description: Fungarium Micromycetes
DOI: 10.48370/ofd/i3qwlk/wtfbop
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-0629.tif

description: :unav
DOI: 10.48370/ofd/i3qwlk
title: Neoërysiphe galeopsidis (DC.) U. Braun, 629

description: Fungarium Micromycetes
DOI: 10.6084/m9.figshare.16646013
title: A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients

description: The aim of this study was to assess acute and late morbidity measured by the physician and patient-reported outcomes (PROs) in high-risk prostate cancer (PC) patients receiving whole pelvic intensity-modulated radiotherapy (IMRT) in the setting of a national clinical trial. A total of 88 patients with adenocarcinoma of the prostate and high-risk parameters were enrolled from 2011 to 2013. All patients received 78 Gy in 39 fractions of IMRT delivering simultaneous 78 Gy to the prostate and 56 Gy to the seminal vesicles and lymph nodes. Physician-reported morbidity was assessed by CTCAE v.4.0. PROs were registered for gastro-intestinal (GI) by the RT-ARD score, genito-urinary (GU) by DAN-PSS, sexual and hormonal by EPIC-26, and quality of life (QoL) by EORTC QLQ-C30. Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence of CTCAE grade 2+ GI morbidities varied from 0 to 6% at baseline throughout FU time, except for diarrhea, which was reported in 19% of the patients post-RT. PROs revealed increased GI morbidity (≥1 monthly episode) for "rectal urgency", "use of pads", "incomplete evacuation", "mucus in stool" and "bowel function impact on QoL" all remained significantly different (<i>p</i> Whole pelvic RT resulted in a mild to the moderate burden of late GI morbidities demonstrated by a relatively high prevalence of PROs. Whereas, physician-assessed morbidity revealed a low prevalence of late GI morbidity scores. This emphasizes the importance of using both PROs and physician-reported scoring scales when reporting late morbidity in clinical trials.
DOI: 10.5281/zenodo.5957259
title: Dataset related to article "Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis "

description: This record contains raw data related to article “Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis" Adrenal metastases occur in 15-35% of oncological patients. Surgery is the first treatment option. Stereotactic body radiotherapy (SBRT) has been largely explored in oligometastatic patients unfit for surgery, representing an effective and non-invasive local treatment. The results of a multi-institutional experience of SBRT on adrenal metastases in the oligorecurrent or oligoprogressive setting are herein reported. We collected data of adrenal gland metastases treated with SBRT in three Italian centers from 2010 to 2020. End-points of the present study were: Overall survival (OS), Local control of treated metastases (LC), Progression free survival (PFS), and toxicity. 149 adrenal gland metastases were treated with SBRT in 142 patients. The most common primary tumor was lung cancer (58.4%), followed by kidney cancer (9.4%). Median lesion's volume was 28.5 cm<sup>3</sup> (2.5-323.4). The median SBRT dose was 40 Gy (10-60). Median follow-up was 14.4 months. One- and two-year OS were 72.3% and 53.5%. At univariate analysis performance status correlated with survival (HR 1.57, p = 0.006). One- and two-year LC were 85.4% and 79.2%, with lung primary tumor (HR 0.33, p = 0.021) and BED10 (HR 0.97, p = 0.036) significant independent factors. One- and two-year PFS were 37.7% and 24.8%. Median time to polymetastatic disease was 11.3 months. Grade 1 and 2 toxicity occurred in 21 (14.7%) and 3 (2.1%) patients. The results from this large multi-center study confirm the efficacy and safety of SBRT in the management of adrenal gland metastases, as a valid alternative to other more invasive local approaches.
DOI: 10.6084/m9.figshare.16543237
title: Retrospective validation of coverage probability based simultaneous integrated nodal boost in locally advanced cervical cancer: a mono-institutional analysis

description: Retrospective validation of coverage probability based simultaneous integrated nodal boost in locally advanced cervical cancer: a mono-institutional analysis
DOI: 10.5281/zenodo.5957258
title: Dataset related to article "Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis "

description: This record contains raw data related to article “Stereotactic body radiation therapy for adrenal gland metastases: outcome and predictive factors from a multicenter analysis" Adrenal metastases occur in 15-35% of oncological patients. Surgery is the first treatment option. Stereotactic body radiotherapy (SBRT) has been largely explored in oligometastatic patients unfit for surgery, representing an effective and non-invasive local treatment. The results of a multi-institutional experience of SBRT on adrenal metastases in the oligorecurrent or oligoprogressive setting are herein reported. We collected data of adrenal gland metastases treated with SBRT in three Italian centers from 2010 to 2020. End-points of the present study were: Overall survival (OS), Local control of treated metastases (LC), Progression free survival (PFS), and toxicity. 149 adrenal gland metastases were treated with SBRT in 142 patients. The most common primary tumor was lung cancer (58.4%), followed by kidney cancer (9.4%). Median lesion's volume was 28.5 cm<sup>3</sup> (2.5-323.4). The median SBRT dose was 40 Gy (10-60). Median follow-up was 14.4 months. One- and two-year OS were 72.3% and 53.5%. At univariate analysis performance status correlated with survival (HR 1.57, p = 0.006). One- and two-year LC were 85.4% and 79.2%, with lung primary tumor (HR 0.33, p = 0.021) and BED10 (HR 0.97, p = 0.036) significant independent factors. One- and two-year PFS were 37.7% and 24.8%. Median time to polymetastatic disease was 11.3 months. Grade 1 and 2 toxicity occurred in 21 (14.7%) and 3 (2.1%) patients. The results from this large multi-center study confirm the efficacy and safety of SBRT in the management of adrenal gland metastases, as a valid alternative to other more invasive local approaches.
DOI: 10.6084/m9.figshare.16646013.v1
title: A phase I/II study of acute and late physician assessed and patient-reported morbidity following whole pelvic radiation in high-risk prostate cancer patients

description: The aim of this study was to assess acute and late morbidity measured by the physician and patient-reported outcomes (PROs) in high-risk prostate cancer (PC) patients receiving whole pelvic intensity-modulated radiotherapy (IMRT) in the setting of a national clinical trial. A total of 88 patients with adenocarcinoma of the prostate and high-risk parameters were enrolled from 2011 to 2013. All patients received 78 Gy in 39 fractions of IMRT delivering simultaneous 78 Gy to the prostate and 56 Gy to the seminal vesicles and lymph nodes. Physician-reported morbidity was assessed by CTCAE v.4.0. PROs were registered for gastro-intestinal (GI) by the RT-ARD score, genito-urinary (GU) by DAN-PSS, sexual and hormonal by EPIC-26, and quality of life (QoL) by EORTC QLQ-C30. Median follow-up (FU) time was 4.6 years. No persistent late CTCAE grade 3+ morbidity was observed. Prevalence of CTCAE grade 2+ GI morbidities varied from 0 to 6% at baseline throughout FU time, except for diarrhea, which was reported in 19% of the patients post-RT. PROs revealed increased GI morbidity (≥1 monthly episode) for "rectal urgency", "use of pads", "incomplete evacuation", "mucus in stool" and "bowel function impact on QoL" all remained significantly different (<i>p</i> Whole pelvic RT resulted in a mild to the moderate burden of late GI morbidities demonstrated by a relatively high prevalence of PROs. Whereas, physician-assessed morbidity revealed a low prevalence of late GI morbidity scores. This emphasizes the importance of using both PROs and physician-reported scoring scales when reporting late morbidity in clinical trials.
DOI: 10.6084/m9.figshare.17988720
title: Mucosa-sparing dose painting of head and neck cancer

description: Mucosa-sparing dose painting of head and neck cancer
DOI: 10.6084/m9.figshare.17988720.v1
title: Mucosa-sparing dose painting of head and neck cancer

description: Mucosa-sparing dose painting of head and neck cancer
DOI: 10.48370/ofd/bpjulv/hpsaqv
title: Neoërysiphe galeopsisdis (DC.) U. Braun F-0701.tif

description: :unav